2-[benzyl-(4-methoxyphenyl)sulfonylamino]-5-(diethylaminomethyl)-N-hydroxy-3-methylbenzamide manufacturers
|
| | 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-5-(diethylaminomethyl)-N-hydroxy-3-methylbenzamide Basic information |
| | 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-5-(diethylaminomethyl)-N-hydroxy-3-methylbenzamide Chemical Properties |
| density | 1.250±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 20 mg/ml; DMSO: 25 mg/ml; Ethanol: 33 mg/ml; Ethanol:PBS (pH 7.2) (1:8): 0.11 mg/ml | | form | A solid | | pka | 8.23±0.42(Predicted) | | color | White to off-white |
| | 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-5-(diethylaminomethyl)-N-hydroxy-3-methylbenzamide Usage And Synthesis |
| Description | MMP-9 inhibitor I is an inhibitor of matrix metalloproteinase-9 (MMP-9) that is selective over MMP-1 and MMP-13 (IC50s = 5, 1,050, and 113 nM, respectively).1 It also decreases the activity of TNF-α converting enzyme (TACE) in a dose-dependent manner (IC50 = 0.54 μM).2 MMP-9 inhibitor I decreases TNF-α secretion stimulated by LPS in BV-2 microglial cells when used at concentrations of 50 and 100 μM. | | Uses | MMP-9-IN-9 (compound 4f) is a slective MMP-9 inhibitor with an IC50 of 5 nM. MMP-9-IN-9 shows selective for MMP-9 over MMP-1 and MMP-13. MMP-9-IN-9 shows strong anti-inflammatory and neuroprotective effects[1]. | | Definition | ChEBI: MMP9 inhibitor I is a hydroxamic acid that is N-hydroxy-3-methylbenzamide in which the the hydrogens at positions 2 and 5 have been replaced by benzyl[(4-methoxyphenyl)sulfonyl]amino and (diethylamino)methyl groups, respectively. It is a cell-permeable, potent, selective, and reversible inhibitor of matrix metallopeptidase-9 (MMP-9, EC 3.4.24.35). It has a role as an EC 3.4.24.35 (gelatinase B) inhibitor. It is a hydroxamic acid, a tertiary amino compound, a sulfonamide and an aromatic ether. | | IC 50 | MMP-9: 5 nM (IC50); MMP-1: 1050 nM (IC50); MMP-13: 113 nM (IC50) | | References | 1. Levin, J.I., Chen, J., Du, M., et al. The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P11 groups Bioorg. Med. Chem. Lett. 11(16),2189-2192(2001).
2. Lee, E.-J., Moon, P.-G., Baek, M.-C., et al. Comparison of the effects of matrix metalloproteinase inhibitors on TNF-α release from activated microglia and TNF-α converting enzyme activity Biomol. Ther. (Seoul) 22(5),414-419(2014). |
| | 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-5-(diethylaminomethyl)-N-hydroxy-3-methylbenzamide Preparation Products And Raw materials |
|